Business Strategy CEOs

  • GoPro 'uncorks' massive content: CEO

    GoPro founder and CEO Nick Woodman. discusses his company's vision to grow the company into a "compelling" content company.

  • GoPro: The original 'selfie'

    GoPro Founder and CEO Nick Woodman. shares his story on how he came up with the idea to create the GoPro camera.

  • Alcoa buys Firth Rixson for $2.8B

    With this acquisition we are adding 20 percent to our aerospace business, says Klaus Kleinfeld, Alcoa chairman & CEO, discussing his company's rapid expansion into the aerospace space.

  • IMAX's 3D future 'transforming': CEO

    China is going to be the big game changer, says IMAX CEO Richard Gelfond, discussing the release of "Transformers: Age of Extinction," the first feature film to use the new IMAX 3D digital camera.

  • Encourage Aereo to play by rules: Pro

    Discussing the future of broadcasting and if a business opportunity still exists for companies with Aereo's business model, with Gordon Smith, National Association of Broadcasters president and CEO, and Vincent Sadusky LIN Media president & CEO.

  • CBS CEO on consolidation: Our job to provide top content

    CBS CEO Leslie Moonves discusses the likelihood of consolidation in the content provider industry, and the state of CBS' business.

  • CBS CEO: Terrific victory for content business

    CBS CEO Leslie Moonves shares his view of the U.S. Supreme Court's Aereo ruling, saying "we're not against our content in the cloud as long as we're getting paid for it." Moonves discusses Aereo's business model.

  • Barnes & Noble splitting

    CNBC's David Faber speaks to Michael Huseby, Barnes & Noble CEO, about the company's decision to split its retail and Nook Media businesses into two separate public companies looking to boost shareholder value.

  • Clients want innovation in advertising: CEO

    Bob Jeffrey, chairman and chief executive at JWT Worldwide, says clients want advertising that is "leading innovation".

  • Vertex CEO on big cystic fibrosis breakthrough

    CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."

  • Dov Charney

    Here's what Dov Charney would have to do to keep his job as American Apparel president and CEO, says law professor Dan Eaton.

  • Carnival CEO: Increased guidance for year

    The world's largest cruise ship operator Carnival Corp. beat profit estimates for the last 3 months. Its CEO Arnold Donald provides insight to the improvements from one year ago.

  • Nestle USA CEO: Constantly looking to acquire

    Nestle USA chairman & CEO Paul Grimwood, discuss how inflation is impacting food prices and where the company is looking to expand its health and wellness ambition.

  • Russell Indexes CEO celebrates 30th anniversary

    Russell Indexes' reconstitution concludes at the market close on Friday. Ron Bundy, Russell Indexes CEO, provides insight to the company's annual rebalance.

  • IT business due for a refresh: CEO

    Alain Monie, Ingram Micro CEO, shares his thoughts on the rise in IT spending and the global tech supply chain.

  • Dov Charney

    Dov Charney’s dismissal raises all sorts of thorny corporate-governance questions for investors and boards about iconic — and notorious — leaders.

  • Europe needs a single energy market: Enel CEO

    Francesco Starace, CEO of Enel, says Europe has "structural issues" in its energy industry that can be resolved by creating a single market.

  • Demographics driving EM energy demand: Enel CEO

    Francesco Starace, CEO of Enel, says a young population in Latin America is driving energy demand in the region.

  • Energy regulators 'deserve a break': Enel CEO

    Francesco Starace, CEO of Enel, says regulators in Europe are always late to adapt to new technologies but "deserve a break".

  • Cubist advances Sivextro

    Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.